Eli Lilly
As of the edition of 20 October 2026, Eli Lilly runs 369 drugs, 107 of them marketed; it is on route A at 64 targets and on route B at 31 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 107 |
| Active | 76 |
| Went quiet | 85 |
| Stopped | 72 |
| Withdrawn from market | 4 |
| Status not established | 25 |
| Total | 369 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Gemcitabine | none listed | 1 |
| Pemetrexed | none listed | 7 |
| Vincristine | none listed | 0 |
| Cetuximab | Ended 2016 (computed from the first US licence) | 2 |
| Insulin human | Ended 1994 (computed from the first US licence) | 1 |
| Insulin glargine | Ended 2012 (computed from the first US licence) | 0 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Olanzapine | none listed | 5 |
| Duloxetine | none listed | 2 |
| Progesterone | none listed | 3 |
| Exenatide | Ended 2025 (patent) | 1 |
| Abemaciclib | Ends 2031 (patent) | 2 |
| Testosterone | none listed | 4 |
| Vancomycin | none listed | 0 |
| Folic acid | none listed | 0 |
| Tirzepatide | Ends 2039 (patent) | 1 |
| Tadalafil | none listed | 3 |
| Fluoxetine | none listed | 1 |
| Heparin | none listed | 5 |
| Ramucirumab | Ended 2026 (orphan exclusivity) | 1 |
| Baricitinib | Ends 2032 (patent) | 4 |
| Vinblastine | none listed | 0 |
| Isoniazid | none listed | 0 |
| Methadone | none listed | 2 |
| Atomoxetine | none listed | 0 |
A route B row is one company at one target. 82 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 64 targets, route B at 31 targets.
All 95 rows on route A or B
In the product95 company-target rows on route A or B; 92 are not shown here, and no score is.
See all 95 targets where Eli Lilly needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 412 trials led
- Nutrition and metabolism: 332 trials led
- Hormones: 258 trials led